Thorough Future develops AI and big-data solutions that provide intelligent classification, diagnosis, and prediction for pathology images and delivers optimized diagnostic workflows. The company aims to support long‑term digitization, informatization, and intelligent transformation of pathology departments across China and the Asia‑Pacific region. It offers a智慧病理 (smart pathology) diagnosis platform and related services to improve diagnostic efficiency and accuracy. Recently the company completed an A+ financing round of nearly ¥100 million. Proceeds are earmarked for upgrading its intelligent pathology diagnosis platform, researching and developing large models, and promoting digital‑intelligent pathology departments. No operating metrics or founding year were disclosed in the article. Founded in 2017, 透彻影像 develops AI-driven pathology tools including the Thorough Insights diagnostic platform, Thorough ESD for automated ESD pathology mapping, and Thorough Wisdom for image annotation. Its platforms automatically identify lesion regions, generate auxiliary diagnostic reports into LIS, and accelerate ESD pathology workflows from hours to under 15 minutes. The company also built a distributed pathology image storage and analysis system with linear GPU scaling and claims a single server can analyze a 1GB pathology image in about 20 seconds. Its annotation system supports over one million high-precision annotations and a multi-level clinical review process with more than 40 experienced pathologists. 透彻影像 has secured collaborations with top Chinese hospitals and holds more than 20 software copyrights, nearly 10 patent applications (three granted), and published work accepted at ICCV2019. Following the recent financing, the company plans to continue AI product R&D, conduct multi-center testing, pursue NMPA registration, accelerate hardware integration, and deepen market penetration.

Total raised

$14M

Funding rounds

2

Latest round

Series A

Latest activity

Jun 2024